Biodexa Pharmaceuticals PLC: CSO/CMO Departs

TL;DR

Biodexa Pharmaceuticals PLC's CSO/CMO, Dmitry Zamoryakhin, has stepped down as of July 4, 2024.

AI Summary

Biodexa Pharmaceuticals PLC announced the departure of Dmitry Zamoryakhin as Chief Scientific Officer and Chief Medical Officer, effective July 4, 2024. The company, previously known as Midatech Pharma Plc, is incorporated in the UK and its principal executive offices are located in Cardiff. This filing is a Form 6-K report for the month of July 2024.

Why It Matters

The departure of key scientific and medical leadership can signal shifts in a pharmaceutical company's research and development strategy or operational focus.

Risk Assessment

Risk Level: medium — The departure of a Chief Scientific Officer and Chief Medical Officer can indicate potential changes in R&D direction or internal challenges.

Key Players & Entities

• Biodexa Pharmaceuticals PLC (company) — Registrant
• Dmitry Zamoryakhin (person) — Departing Chief Scientific Officer and Chief Medical Officer
• July 4, 2024 (date) — Effective date of departure
• Midatech Pharma Plc (company) — Former company name

FAQ

Filing Documents

• b752476k.htm (6-K) — 9KB
• 0001214659-24-012031.txt ( ) — 10KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2024 Commission File Number 001-37652 Biodexa Pharmaceuticals PLC (Translation of registrant’s name into English) 1 Caspian Point, Caspian Way Cardiff, CF10 4DQ, United Kingdom (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ EXPLANATORY NOTE Departure of Directors or Certain Officers Effective July 4, 2024, Dmitry Zamoryakhin, Chief Scientific Officer and Chief Medical Officer of Biodexa Pharmaceuticals PLC (the “Company”) departed the Company. The Company has appointed a consultant to fulfill the role of Chief Medical Officer on an interim basis until such time as a permanent replacement is appointed. The information included in this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File No. 333-214969) and Form F-3 (File No. 333-233901) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC Date: July 5, 2024 By: /s/ Stephen Stamp Stephen Stamp Chief Executive Officer and Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR